Caseware UK (AP4) 2022.0.179 2022.0.179 2023-12-312023-12-312023-01-01falseNo description of principal activity124falsetrueThe members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.false SC624281 2023-01-01 2023-12-31 SC624281 2022-04-01 2022-12-31 SC624281 2023-12-31 SC624281 2022-12-31 SC624281 c:Director1 2023-01-01 2023-12-31 SC624281 c:Director3 2023-01-01 2023-12-31 SC624281 c:Director4 2023-01-01 2023-12-31 SC624281 c:Director5 2023-01-01 2023-12-31 SC624281 c:RegisteredOffice 2023-01-01 2023-12-31 SC624281 d:PlantMachinery 2023-01-01 2023-12-31 SC624281 d:PlantMachinery 2023-12-31 SC624281 d:PlantMachinery 2022-12-31 SC624281 d:PlantMachinery d:OwnedOrFreeholdAssets 2023-01-01 2023-12-31 SC624281 d:CurrentFinancialInstruments 2023-12-31 SC624281 d:CurrentFinancialInstruments 2022-12-31 SC624281 d:CurrentFinancialInstruments d:WithinOneYear 2023-12-31 SC624281 d:CurrentFinancialInstruments d:WithinOneYear 2022-12-31 SC624281 d:ShareCapital 2023-12-31 SC624281 d:ShareCapital 2022-12-31 SC624281 d:SharePremium 2023-12-31 SC624281 d:SharePremium 2022-12-31 SC624281 d:RetainedEarningsAccumulatedLosses 2023-12-31 SC624281 d:RetainedEarningsAccumulatedLosses 2022-12-31 SC624281 c:OrdinaryShareClass2 2023-01-01 2023-12-31 SC624281 c:OrdinaryShareClass2 2023-12-31 SC624281 c:OrdinaryShareClass2 2022-12-31 SC624281 c:FRS102 2023-01-01 2023-12-31 SC624281 c:AuditExempt-NoAccountantsReport 2023-01-01 2023-12-31 SC624281 c:FullAccounts 2023-01-01 2023-12-31 SC624281 c:PrivateLimitedCompanyLtd 2023-01-01 2023-12-31 SC624281 2 2023-01-01 2023-12-31 SC624281 e:PoundSterling 2023-01-01 2023-12-31 xbrli:shares iso4217:GBP xbrli:pure
Registered number: SC624281










BLOOM BIOTECHNOLOGIES LIMITED
FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2023

 
BLOOM BIOTECHNOLOGIES LIMITED
 

COMPANY INFORMATION


DIRECTORS
Sir Henry R G Aykroyd Bt 
Dr Jonathan B Snape 
Professor Derek Stewart 
Colin Herron 




REGISTERED NUMBER
SC624281



REGISTERED OFFICE
Mylnefield
Errol road

Invergowrie

Dundee

DD2 5DA




ACCOUNTANTS
EQ Accountants Limited
Chartered Accountants

Westby

64 West High Street

Forfar

Angus

DD8 1BJ





 
BLOOM BIOTECHNOLOGIES LIMITED
REGISTERED NUMBER: SC624281

STATEMENT OF FINANCIAL POSITION
AS AT 31 DECEMBER 2023

2023
2022
Note
£
£

FIXED ASSETS
  

Tangible assets
 4 
17,727
23,639

  
17,727
23,639

CURRENT ASSETS
  

Debtors: amounts falling due within one year
 5 
79,316
212,365

Cash at bank and in hand
  
739
1,686

  
80,055
214,051

Creditors: amounts falling due within one year
 6 
(37,427)
(30,438)

NET CURRENT ASSETS
  
 
 
42,628
 
 
183,613

TOTAL ASSETS LESS CURRENT LIABILITIES
  
60,355
207,252

  

NET ASSETS
  
60,355
207,252


CAPITAL AND RESERVES
  

Called up share capital 
 7 
5
5

Share premium account
  
1,249,998
1,249,998

Profit and loss account
  
(1,189,648)
(1,042,751)

  
60,355
207,252


Page 1

 
BLOOM BIOTECHNOLOGIES LIMITED
REGISTERED NUMBER: SC624281

STATEMENT OF FINANCIAL POSITION (CONTINUED)
AS AT 31 DECEMBER 2023

The directors consider that the Company is entitled to exemption from audit under section 477 of the Companies Act 2006 and members have not required the Company to obtain an audit for the year in question in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime and in accordance with the provisions of FRS 102 Section 1A - small entities.

The financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The Company has opted not to file the statement of income and retained earnings in accordance with provisions applicable to companies subject to the small companies' regime.

The financial statements were approved and authorised for issue by the board and were signed on its behalf on 1 April 2024.




Sir Henry R G Aykroyd Bt
Director

The notes on pages 3 to 7 form part of these financial statements.

Page 2

 
BLOOM BIOTECHNOLOGIES LIMITED
 

 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2023

1.


GENERAL INFORMATION

Bloom Biotechnologies Limited is a private company, limited by shares, incorporated in Scotland with registration number SC624281.  The principle place of business and registered office is Mylnefield, Errol road, Invergowrie, Dundee DD2 5DA.

2.ACCOUNTING POLICIES

 
2.1

BASIS OF PREPARATION OF FINANCIAL STATEMENTS

The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with FRS 102 'The Financial Reporting Standard applicable in the UK and the Republic of Ireland' and the requirements of the Companies Act 2006. The disclosure requirements of Section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The following principal accounting policies have been applied:

 
2.2

FOREIGN CURRENCY TRANSLATION

Functional and presentation currency

The Company's functional and presentational currency is GBP.

Transactions and balances

Foreign currency transactions are translated into the functional currency using the spot exchange rates at the dates of the transactions.

At each period end foreign currency monetary items are translated using the closing rate. Non-monetary items measured at historical cost are translated using the exchange rate at the date of the transaction and non-monetary items measured at fair value are measured using the exchange rate when fair value was determined.

Foreign exchange gains and losses resulting from the settlement of transactions and from the translation at period-end exchange rates of monetary assets and liabilities denominated in foreign currencies are recognised in profit or loss except when deferred in other comprehensive income as qualifying cash flow hedges.

Foreign exchange gains and losses that relate to borrowings and cash and cash equivalents are presented in the Statement of income and retained earnings within 'finance income or costs'. All other foreign exchange gains and losses are presented in profit or loss within 'other operating income'.

Page 3

 
BLOOM BIOTECHNOLOGIES LIMITED
 

 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2023

2.ACCOUNTING POLICIES (CONTINUED)

 
2.3

RESEARCH AND DEVELOPMENT

In the research phase of an internal project it is not possible to demonstrate that the project will generate future economic benefits and hence all expenditure on research shall be recognised as an expense when it is incurred. Intangible assets are recognised from the development phase of a project if and only if certain specific criteria are met in order to demonstrate the asset will generate probable future economic benefits and that its cost can be reliably measured. The capitalised development costs are subsequently amortised on a straight-line basis over their useful economic lives, which range from 3 to 6 years.
If it is not possible to distinguish between the research phase and the development phase of an internal project, the expenditure is treated as if it were all incurred in the research phase only.

Where the company claims for research and development tax relief, the benefit is only recognised within the financial statements once the claim has been submitted and approved by HM Revenue & Customs. 

 
2.4

INTEREST INCOME

Interest income is recognised in profit or loss using the effective interest method.

 
2.5

FINANCE COSTS

Finance costs are charged to profit or loss over the term of the debt using the effective interest method so that the amount charged is at a constant rate on the carrying amount. Issue costs are initially recognised as a reduction in the proceeds of the associated capital instrument.

 
2.6

TAXATION

Tax is recognised in profit or loss except that a charge attributable to an item of income and expense recognised as other comprehensive income or to an item recognised directly in equity is also recognised in other comprehensive income or directly in equity respectively.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the reporting date in the countries where the Company operates and generates income.

 
2.7

TANGIBLE FIXED ASSETS

Tangible fixed assets under the cost model are stated at historical cost less accumulated depreciation and any accumulated impairment losses. Historical cost includes expenditure that is directly attributable to bringing the asset to the location and condition necessary for it to be capable of operating in the manner intended by management.

Page 4

 
BLOOM BIOTECHNOLOGIES LIMITED
 

 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2023

2.ACCOUNTING POLICIES (CONTINUED)


2.7
TANGIBLE FIXED ASSETS (CONTINUED)

Depreciation is charged so as to allocate the cost of assets less their residual value over their estimated useful lives, on a reducing balance basis.

Depreciation is provided on the following basis:

Plant and machinery
-
25%

The assets' residual values, useful lives and depreciation methods are reviewed, and adjusted prospectively if appropriate, or if there is an indication of a significant change since the last reporting date.

Gains and losses on disposals are determined by comparing the proceeds with the carrying amount and are recognised in profit or loss.

 
2.8

FINANCIAL INSTRUMENTS

The Company has elected to apply the provisions of Section 11 “Basic Financial Instruments” of FRS 102 to all of its financial instruments.

Financial instruments are recognised in the Company's Statement of financial position when the Company becomes party to the contractual provisions of the instrument.

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.


3.


EMPLOYEES




The average monthly number of employees, including directors, during the year was 4 (2022 - 12).

Page 5

 
BLOOM BIOTECHNOLOGIES LIMITED
 

 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2023

4.


TANGIBLE FIXED ASSETS





Plant and machinery

£



COST OR VALUATION


At 1 January 2023
48,863



At 31 December 2023

48,863



DEPRECIATION


At 1 January 2023
25,224


Charge for the year on owned assets
5,912



At 31 December 2023

31,136



NET BOOK VALUE



At 31 December 2023
17,727



At 31 December 2022
23,639


5.


DEBTORS

2023
2022
£
£


Amounts owed by group undertakings
63,443
36,760

Other debtors
2,237
1,930

Prepayments and accrued income
13,636
173,675

79,316
212,365



6.


CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

2023
2022
£
£

Trade creditors
-
95

Other creditors
35,712
28,343

Accruals and deferred income
1,715
2,000

37,427
30,438


Page 6

 
BLOOM BIOTECHNOLOGIES LIMITED
 

 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2023

7.


SHARE CAPITAL

2023
2022
£
£
ALLOTTED, CALLED UP AND FULLY PAID



45 (2022 - 45) ordinary shares of £0.10 each
4.50
4.50



Page 7